Chronic liver disease is known as the silent killer, showing no obvious symptoms until the disease has progressed to an advanced stage. Therefore, making a proper diagnosis in the early stage of disease progression a clinical challenge. An international team of researchers, affiliated with UNIST, has identified a novel route that regulates the…...
Molecular profiling could catch lung cancer early and lead to new treatments
Before lung cancer develops, precancerous lesions are found in the airway, but only some of these will actually become lung cancer, while others will disappear or remain benign without becoming harmful. Under the microscope, the lesions look the same, making it difficult to know which lesions to treat. A new…...
Antibodies to a retina protein to be used as a kidney cancer marker
Tumors can be benign or malignant. Benign tumors can evolve into malignant ones. Around 90 to 93% of all kidney growths turn out to be malignant, and there are currently no effective methods for early diagnostics. The initial stages of kidney cancer have no signs or specific symptoms, so patients are often…...
What happens if chemotherapy does not work?
Chemotherapy is used by doctors to either as a first-line therapy or in combination with other treatments, such as surgery, to treat cancer. If chemotherapy does not work, a person may need to consider other treatment options. Signs that the cancer is not responding to chemotherapy include the growing or spreading…...
DNA origami: A precise measuring tool for optimal antibody effectiveness
Using DNA-based designs of precise nanostructures — scientists have been able to demonstrate the most accurate distance between densely packed antigens in order to get the strongest bond to antibodies in the immune system. The study may be of significance to the development of vaccines and immunotherapy used in cancer.…...
A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors
In the United States, it is estimated that more than 1.7 million people will be diagnosed with cancer, and more than 600,000 will die of the disease in 2018. The financial costs associated with cancer risk factors and cancer care are enormous. To substantially reduce both the number of individuals…...
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new…...
- 1
- 2